ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Status:
Terminated
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and
safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation
in patients with dementia, including Alzheimer's disease.